First head-to-head comparison of Gla-300 versus Ideg-100
- Both the incidence and the prevalence of diabetes have steadily increased over the past few decades. Despite using insulin, it has been found that 8 out of 10 patients do not reach their target HbA1c, which should be below 7.0 %.
- This could be brought on by a lack of adherence among individuals as a way of avoiding hypoglycemia. In order to establish effective glycemic control in diabetics, it is crucial to titrate the basal insulin as part of the optimal management the condition. The initial 12 weeks of insulin administration is the most important period to achieve that.
- Insulin Glargine (Gla-300) and Insulin Degludec (IDeg-100), two second-generation basal insulins, were compared in the Bright study, and while both randomized groups had good glycemic control, Gla-300 demonstrated a 23% lower incidence and rate of nocturnal confirmed hypoglycemia (70 mg/dL) than IDeg-100 during the initial titration period. Watch this presentation by Dr. Sunil M. Jain as he provides us with further insights on basal insulin.